Praeruptorin A: A Next-Generation Ferroptosis and DMT1 Inhibitor for Cardiac and Cancer Research

Introduction

Pyranocoumarin derivatives have captured the interest of biomedical researchers due to their diverse bioactivities and therapeutic promise. Among them, Praeruptorin A (CAS No. 73069-27-9), an angular pyranocoumarin compound derived from Peucedanum praeruptorum Dunn, stands out as a unique multi-target modulator. Recent advances have revealed its potent inhibition of ferroptosis and the DMT1 transporter, positioning it at the forefront of translational research in cardiomyopathy, cancer biology, and inflammatory disorders. This article provides an in-depth analysis of Praeruptorin A's molecular mechanisms, safety profile, and advanced applications, with a particular focus on its role as a ferroptosis inhibitor and as a therapeutic agent in doxorubicin-induced cardiomyopathy and metastatic cancer models.

Distinct Scientific Perspective: Beyond Conventional Mechanisms

While previous content has highlighted Praeruptorin A's capacity as an NF-κB pathway inhibitor and its anti-inflammatory effects (see, for example, "Praeruptorin A: Next-Generation Modulator of Inflammation"), this article uniquely synthesizes recent high-throughput screening data and mechanistic insights to reveal Praeruptorin A's pivotal action as a ferroptosis inhibitor via DMT1 suppression. We further examine the translational impact across organ systems, highlighting innovative applications in both cardiac and oncology research that extend beyond established pathways.

Chemical Profile and Bioavailability

Structural and Physicochemical Features

Praeruptorin A (C₂₁H₂₂O₇, MW 386.40) is characterized by its angular pyranocoumarin scaffold, which is known to confer both high membrane permeability and target specificity. As a small molecule, its bioavailability is supported by its solubility: it dissolves at ≥50.8 mg/mL in DMSO and ≥12.68 mg/mL in ethanol (with ultrasonic treatment), but is insoluble in water. This profile supports diverse in vitro and in vivo applications, with reported effective concentrations ranging from 0.4 μM to 75 μg/mL, and in vivo dosing typically at 0.8–1.2 mg/kg/day (i.p.) or 30 mg/kg/day (oral gavage) in murine models.

Stability and Handling Considerations

Solutions of Praeruptorin A should be freshly prepared and stored at 4°C, protected from light, to maintain stability. Long-term storage of prepared solutions is not recommended. These properties ensure reliable experimental reproducibility, a critical parameter for translational research.

Mechanism of Action: From DMT1 Inhibition to Ferroptosis Suppression

DMT1 as a Central Axis in Ferroptosis

Ferroptosis, an iron-dependent form of regulated cell death, is increasingly recognized as a key driver of tissue injury in various pathological contexts, including doxorubicin-induced cardiomyopathy (DIC) and cancer. Divalent Metal Transporter 1 (DMT1) mediates cellular uptake of Fe²⁺, and its dysregulation results in iron overload, lipid peroxidation, and ultimately cell death. Targeting DMT1 thus represents a rational strategy for modulating ferroptosis and its downstream effects.

Praeruptorin A: A Selective DMT1 Inhibitor

Recent work by Li et al. (European Journal of Medicinal Chemistry, 2025) established Praeruptorin A as a selective DMT1 inhibitor, identified through high-throughput screening with Fe²⁺ probes. The study demonstrated that Praeruptorin A downregulates DMT1 expression, effectively suppressing Fe²⁺ overload in both cardiomyocytes and murine hearts. This intervention mitigated ferroptosis, reduced lipid peroxidation, and preserved cardiac function in mouse models of DIC. These findings not only validate the DMT1-ferroptosis axis as a therapeutic target but also position Praeruptorin A as a first-in-class small molecule modulator in this pathway.

Multi-Target Modulation: Beyond Ferroptosis

In addition to DMT1, Praeruptorin A interacts with multiple signaling molecules and pathways:

• STAT-1/3 Signaling Inhibition: Suppression of STAT-1/3 phosphorylation attenuates inflammatory cytokine production (TNF-α, IL-6, IL-1β), while upregulating anti-inflammatory factors (IL-10, TGF-β).
• NF-κB Pathway Inhibition: Inhibition of p65 and p38 activation leads to downregulation of PTGS2 and HMOX1, further curtailing inflammatory responses.
• ERK1/2 Signaling Pathway: Downregulation of MMP1 via ERK1/2 inhibition impairs migration and invasion of hepatocellular carcinoma cells, suggesting anti-metastatic potential.

These pleiotropic effects support Praeruptorin A's utility across a spectrum of disease models, from inflammatory bowel disease to metastatic cancer.

Comparative Analysis: Praeruptorin A Versus Conventional and Emerging Approaches

Dexrazoxane and the Iron Chelation Paradigm

Dexrazoxane (DXZ) remains the only FDA-approved agent for prevention of doxorubicin-induced cardiotoxicity, primarily acting through iron chelation. However, DXZ’s clinical adoption is limited by concerns over its impact on chemotherapy efficacy and potential off-target effects. Praeruptorin A’s mechanism—inhibiting DMT1-mediated iron uptake upstream of iron overload—offers a more targeted approach, potentially avoiding the drawbacks of direct chelation while still mitigating ferroptosis and cardiac injury.

Expanding Beyond Inflammation: Towards Integrated Disease Models

While previous reviews, such as "Praeruptorin A: Translating Multi-Targeted Mechanism into...", have emphasized the compound’s impact on inflammation and osteoclast apoptosis, our present analysis extends these findings by focusing on the integration of iron metabolism, cell death regulation, and anti-metastatic activity. This approach not only consolidates Praeruptorin A’s established anti-inflammatory profile but also frames it within the context of ferroptosis biology and advanced cancer therapeutics.

Advanced Applications in Cardiomyopathy and Cancer Biology

Cardiomyopathy Research: Preclinical Validation

The role of ferroptosis in DIC is well-supported, with Praeruptorin A demonstrating robust cardioprotective effects in vivo. Li et al. (2025) reported that Praeruptorin A reduced Fe²⁺ accumulation, suppressed ferroptotic cell death, and improved cardiac function in DOX-treated mice. Importantly, the compound exhibited a favorable safety profile, with no significant cytotoxicity or multi-organ toxicity at effective doses. These findings offer a compelling alternative to traditional iron chelators and set the stage for further translational research in cardioprotection.

Cancer Biology: Synergistic Antitumor Activity and Metastasis Inhibition

Praeruptorin A’s ability to synergistically enhance doxorubicin’s antitumor effects, as demonstrated in breast cancer xenograft models, opens new avenues for combination therapy. By simultaneously protecting cardiac tissue and sensitizing tumor cells to chemotherapy, Praeruptorin A uniquely addresses a critical unmet need in oncology: improving therapeutic windows without compromising efficacy. Furthermore, its inhibition of MMP1 via the ERK1/2 pathway suppresses migration and invasion in hepatocellular carcinoma models, highlighting its role as a hepatocellular carcinoma metastasis inhibitor.

Ulcerative Colitis and Intestinal Barrier Repair

Pushing beyond established anti-inflammatory paradigms, Praeruptorin A has been shown to inhibit colonic epithelial apoptosis and restore intestinal barrier proteins (ZO-1, occludin, claudin-1), thereby alleviating ulcerative colitis in preclinical models. This multifaceted mechanism distinguishes it from standard anti-inflammatory agents and supports its application as an anti-inflammatory agent for ulcerative colitis.

For readers interested in practical guidance for integrating Praeruptorin A into experimental workflows, including cell viability and cytotoxicity assays, see the scenario-based discussion in "Praeruptorin A (SKU N2885): Scenario-Driven Best Practice...". Our present article expands on these insights by contextualizing Praeruptorin A's mechanistic depth within emerging disease models and translational research pipelines.

Safety, Dosing, and Experimental Considerations

• In Vitro: Effective concentrations range from 0.4 μM (for sensitive cell types) to 75 μg/mL, depending on the biological context.
• In Vivo: Typical doses include 0.8–1.2 mg/kg/day (intraperitoneally) or 30 mg/kg/day (oral) in mouse models.
• Solubility: Dissolves readily in DMSO and ethanol; not water-soluble, necessitating careful formulation for in vivo use.
• Safety: No significant cytotoxicity or multi-organ damage observed at effective doses in preclinical studies.

The broad safety margin and robust efficacy profile make Praeruptorin A from APExBIO a compelling candidate for further preclinical and translational research across multiple disease models.

Conclusion and Future Outlook

Praeruptorin A exemplifies the next generation of small molecule modulators in biomedical research. By targeting the DMT1-ferroptosis axis, modulating NF-κB and ERK1/2 signaling pathways, and demonstrating efficacy in cardiomyopathy, ulcerative colitis, and cancer models, it bridges foundational mechanistic insights with translational promise. The compound’s favorable safety and pharmacological profiles, coupled with its multi-modal action, underscore its value for advanced research and potential clinical translation.

This article has aimed to provide a deeper mechanistic and translational perspective than prior reviews, which have focused predominantly on pathway modulation or experimental protocols. For readers seeking a comprehensive understanding of Praeruptorin A’s broader research value, our synthesis reveals new opportunities for therapeutic innovation and interdisciplinary collaboration. By integrating recent breakthroughs in ferroptosis biology and disease modeling, we encourage the scientific community to harness the full potential of Praeruptorin A as a versatile tool in preclinical and translational research.